 |
|
|
| |
ACH-3422, a Novel Nucleotide Prodrug Inhibitor of HCV NS5B Polymerase
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Frank Weilert5, Katherine Stuart6, Wendy Cheng7, Joanna Yang8, Heather Robison8, James Hui8, John Lahey8, Robert Sorensen8, David Apelian8, Robert Hindes8
Affiliations: 1Auckland Clinical Studies Ltd, Grafton, New Zealand; 2Auckland City Hospital, Auckland, New Zealand; 3Christchurch Clinical Studies Trust and 4Christchurch Hospital, Christchurch, New Zealand; 5Waikato Hospital and Waikato District health Board, Hamilton, New Zealand; 6Q-Pharm Pty Ltd and Gallipoli Medical Research Foundation, Brisbane, Australia; 7Linear Clinical Research and Royal Perth Hospital, Perth, Australia; 8Achillion Pharmaceuticals, New Haven, CT, USA
|
| |
|
|
|
|
|
